Intrinsic value of Allscripts Healthcare Solutions - MDRX

Previous Close

$13.00

  Intrinsic Value

$30.82

stock screener

  Rating & Target

str. buy

+137%

  Value-price divergence*

+2377%

Previous close

$13.00

 
Intrinsic value

$30.82

 
Up/down potential

+137%

 
Rating

str. buy

 
Value-price divergence*

+2377%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of MDRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  11.83
  19.40
  17.96
  16.66
  15.50
  14.45
  13.50
  12.65
  11.89
  11.20
  10.58
  10.02
  9.52
  9.07
  8.66
  8.29
  7.96
  7.67
  7.40
  7.16
  6.95
  6.75
  6.58
  6.42
  6.28
  6.15
  6.03
  5.93
  5.84
  5.75
  5.68
Revenue, $m
  1,550
  1,851
  2,183
  2,547
  2,942
  3,367
  3,821
  4,305
  4,816
  5,356
  5,922
  6,516
  7,136
  7,783
  8,457
  9,159
  9,888
  10,646
  11,434
  12,253
  13,104
  13,989
  14,909
  15,865
  16,861
  17,898
  18,978
  20,103
  21,277
  22,501
  23,779
Variable operating expenses, $m
 
  1,486
  1,718
  1,972
  2,248
  2,545
  2,863
  3,201
  3,558
  3,935
  4,331
  4,554
  4,987
  5,439
  5,910
  6,401
  6,910
  7,440
  7,991
  8,563
  9,158
  9,776
  10,419
  11,088
  11,784
  12,508
  13,263
  14,050
  14,870
  15,725
  16,618
Fixed operating expenses, $m
 
  224
  230
  236
  242
  248
  254
  260
  267
  274
  280
  287
  295
  302
  309
  317
  325
  333
  342
  350
  359
  368
  377
  386
  396
  406
  416
  427
  437
  448
  459
Total operating expenses, $m
  1,490
  1,710
  1,948
  2,208
  2,490
  2,793
  3,117
  3,461
  3,825
  4,209
  4,611
  4,841
  5,282
  5,741
  6,219
  6,718
  7,235
  7,773
  8,333
  8,913
  9,517
  10,144
  10,796
  11,474
  12,180
  12,914
  13,679
  14,477
  15,307
  16,173
  17,077
Operating income, $m
  60
  140
  235
  339
  452
  574
  704
  844
  991
  1,147
  1,311
  1,675
  1,854
  2,042
  2,237
  2,441
  2,652
  2,873
  3,102
  3,340
  3,587
  3,845
  4,112
  4,391
  4,681
  4,984
  5,299
  5,627
  5,970
  6,327
  6,701
EBITDA, $m
  232
  403
  510
  627
  755
  893
  1,041
  1,198
  1,365
  1,541
  1,726
  1,920
  2,123
  2,335
  2,556
  2,786
  3,025
  3,274
  3,532
  3,801
  4,081
  4,372
  4,674
  4,989
  5,317
  5,658
  6,014
  6,385
  6,772
  7,175
  7,597
Interest expense (income), $m
  42
  56
  78
  101
  127
  155
  186
  218
  253
  289
  328
  368
  411
  455
  501
  549
  599
  651
  705
  762
  820
  881
  944
  1,010
  1,078
  1,149
  1,223
  1,300
  1,381
  1,464
  1,552
Earnings before tax, $m
  -15
  84
  157
  237
  324
  418
  519
  625
  738
  858
  983
  1,307
  1,444
  1,587
  1,736
  1,892
  2,053
  2,221
  2,396
  2,578
  2,767
  2,964
  3,168
  3,381
  3,603
  3,834
  4,075
  4,327
  4,589
  4,863
  5,149
Tax expense, $m
  -18
  23
  42
  64
  88
  113
  140
  169
  199
  232
  265
  353
  390
  428
  469
  511
  554
  600
  647
  696
  747
  800
  855
  913
  973
  1,035
  1,100
  1,168
  1,239
  1,313
  1,390
Net income, $m
  3
  62
  115
  173
  237
  305
  379
  456
  539
  626
  717
  954
  1,054
  1,158
  1,267
  1,381
  1,499
  1,622
  1,749
  1,882
  2,020
  2,163
  2,313
  2,468
  2,630
  2,799
  2,975
  3,159
  3,350
  3,550
  3,759

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  97
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  3,832
  4,460
  5,260
  6,137
  7,088
  8,112
  9,208
  10,373
  11,606
  12,905
  14,271
  15,701
  17,195
  18,754
  20,378
  22,069
  23,826
  25,654
  27,552
  29,525
  31,576
  33,708
  35,924
  38,230
  40,629
  43,127
  45,729
  48,441
  51,269
  54,219
  57,298
Adjusted assets (=assets-cash), $m
  3,735
  4,460
  5,260
  6,137
  7,088
  8,112
  9,208
  10,373
  11,606
  12,905
  14,271
  15,701
  17,195
  18,754
  20,378
  22,069
  23,826
  25,654
  27,552
  29,525
  31,576
  33,708
  35,924
  38,230
  40,629
  43,127
  45,729
  48,441
  51,269
  54,219
  57,298
Revenue / Adjusted assets
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
Average production assets, $m
  806
  962
  1,135
  1,324
  1,530
  1,751
  1,987
  2,238
  2,505
  2,785
  3,080
  3,388
  3,711
  4,047
  4,398
  4,762
  5,142
  5,536
  5,946
  6,372
  6,814
  7,274
  7,752
  8,250
  8,768
  9,307
  9,868
  10,454
  11,064
  11,700
  12,365
Working capital, $m
  -63
  -159
  -188
  -219
  -253
  -290
  -329
  -370
  -414
  -461
  -509
  -560
  -614
  -669
  -727
  -788
  -850
  -916
  -983
  -1,054
  -1,127
  -1,203
  -1,282
  -1,364
  -1,450
  -1,539
  -1,632
  -1,729
  -1,830
  -1,935
  -2,045
Total debt, $m
  1,331
  1,804
  2,355
  2,959
  3,615
  4,320
  5,075
  5,878
  6,727
  7,623
  8,563
  9,549
  10,578
  11,653
  12,772
  13,936
  15,147
  16,406
  17,715
  19,074
  20,487
  21,956
  23,483
  25,071
  26,724
  28,446
  30,239
  32,107
  34,055
  36,088
  38,209
Total liabilities, $m
  2,600
  3,073
  3,624
  4,228
  4,884
  5,589
  6,344
  7,147
  7,996
  8,892
  9,832
  10,818
  11,847
  12,922
  14,041
  15,205
  16,416
  17,675
  18,984
  20,343
  21,756
  23,225
  24,752
  26,340
  27,993
  29,715
  31,508
  33,376
  35,324
  37,357
  39,478
Total equity, $m
  1,232
  1,387
  1,636
  1,909
  2,204
  2,523
  2,864
  3,226
  3,609
  4,014
  4,438
  4,883
  5,348
  5,833
  6,338
  6,863
  7,410
  7,978
  8,569
  9,182
  9,820
  10,483
  11,172
  11,889
  12,636
  13,413
  14,222
  15,065
  15,945
  16,862
  17,820
Total liabilities and equity, $m
  3,832
  4,460
  5,260
  6,137
  7,088
  8,112
  9,208
  10,373
  11,605
  12,906
  14,270
  15,701
  17,195
  18,755
  20,379
  22,068
  23,826
  25,653
  27,553
  29,525
  31,576
  33,708
  35,924
  38,229
  40,629
  43,128
  45,730
  48,441
  51,269
  54,219
  57,298
Debt-to-equity ratio
  1.080
  1.300
  1.440
  1.550
  1.640
  1.710
  1.770
  1.820
  1.860
  1.900
  1.930
  1.960
  1.980
  2.000
  2.020
  2.030
  2.040
  2.060
  2.070
  2.080
  2.090
  2.090
  2.100
  2.110
  2.120
  2.120
  2.130
  2.130
  2.140
  2.140
  2.140
Adjusted equity ratio
  0.304
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  3
  62
  115
  173
  237
  305
  379
  456
  539
  626
  717
  954
  1,054
  1,158
  1,267
  1,381
  1,499
  1,622
  1,749
  1,882
  2,020
  2,163
  2,313
  2,468
  2,630
  2,799
  2,975
  3,159
  3,350
  3,550
  3,759
Depreciation, amort., depletion, $m
  172
  262
  275
  288
  303
  319
  336
  355
  374
  394
  416
  246
  269
  293
  319
  345
  373
  401
  431
  462
  494
  527
  562
  598
  635
  674
  715
  758
  802
  848
  896
Funds from operations, $m
  323
  324
  390
  462
  540
  625
  715
  811
  913
  1,020
  1,133
  1,199
  1,323
  1,452
  1,586
  1,726
  1,871
  2,023
  2,180
  2,344
  2,514
  2,691
  2,875
  3,066
  3,266
  3,474
  3,690
  3,916
  4,152
  4,398
  4,655
Change in working capital, $m
  54
  -26
  -29
  -31
  -34
  -37
  -39
  -42
  -44
  -46
  -49
  -51
  -53
  -56
  -58
  -60
  -63
  -65
  -68
  -70
  -73
  -76
  -79
  -82
  -86
  -89
  -93
  -97
  -101
  -105
  -110
Cash from operations, $m
  269
  350
  418
  493
  574
  661
  754
  853
  957
  1,067
  1,182
  1,250
  1,376
  1,507
  1,644
  1,786
  1,934
  2,088
  2,248
  2,414
  2,587
  2,767
  2,954
  3,148
  3,351
  3,563
  3,783
  4,013
  4,253
  4,503
  4,765
Maintenance CAPEX, $m
  0
  -58
  -70
  -82
  -96
  -111
  -127
  -144
  -162
  -181
  -202
  -223
  -246
  -269
  -293
  -319
  -345
  -373
  -401
  -431
  -462
  -494
  -527
  -562
  -598
  -635
  -674
  -715
  -758
  -802
  -848
New CAPEX, $m
  -138
  -156
  -173
  -189
  -205
  -221
  -236
  -251
  -266
  -280
  -295
  -309
  -323
  -336
  -350
  -365
  -379
  -394
  -410
  -426
  -443
  -460
  -478
  -498
  -518
  -539
  -562
  -585
  -610
  -637
  -664
Cash from investing activities, $m
  -1,154
  -214
  -243
  -271
  -301
  -332
  -363
  -395
  -428
  -461
  -497
  -532
  -569
  -605
  -643
  -684
  -724
  -767
  -811
  -857
  -905
  -954
  -1,005
  -1,060
  -1,116
  -1,174
  -1,236
  -1,300
  -1,368
  -1,439
  -1,512
Free cash flow, $m
  -885
  135
  176
  222
  273
  329
  391
  457
  529
  605
  685
  719
  808
  902
  1,000
  1,103
  1,210
  1,321
  1,437
  1,557
  1,683
  1,813
  1,948
  2,089
  2,236
  2,388
  2,547
  2,713
  2,885
  3,065
  3,253
Issuance/(repayment) of debt, $m
  660
  500
  552
  604
  655
  706
  755
  803
  850
  895
  941
  985
  1,030
  1,074
  1,119
  1,165
  1,211
  1,259
  1,308
  1,359
  1,413
  1,469
  1,527
  1,589
  1,653
  1,721
  1,793
  1,869
  1,948
  2,032
  2,121
Issuance/(repurchase) of shares, $m
  212
  163
  134
  99
  59
  13
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  865
  663
  686
  703
  714
  719
  755
  803
  850
  895
  941
  985
  1,030
  1,074
  1,119
  1,165
  1,211
  1,259
  1,308
  1,359
  1,413
  1,469
  1,527
  1,589
  1,653
  1,721
  1,793
  1,869
  1,948
  2,032
  2,121
Total cash flow (excl. dividends), $m
  -20
  798
  862
  925
  987
  1,048
  1,145
  1,260
  1,378
  1,500
  1,626
  1,704
  1,838
  1,976
  2,119
  2,267
  2,421
  2,580
  2,745
  2,917
  3,095
  3,282
  3,475
  3,678
  3,889
  4,109
  4,340
  4,581
  4,833
  5,097
  5,374
Retained Cash Flow (-), $m
  176
  -225
  -249
  -273
  -296
  -318
  -341
  -362
  -383
  -404
  -425
  -445
  -465
  -485
  -505
  -526
  -547
  -568
  -591
  -614
  -638
  -663
  -689
  -717
  -746
  -777
  -809
  -843
  -879
  -917
  -957
Prev. year cash balance distribution, $m
 
  70
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  643
  613
  652
  691
  730
  805
  898
  995
  1,096
  1,201
  1,259
  1,373
  1,491
  1,614
  1,742
  1,874
  2,012
  2,155
  2,303
  2,458
  2,619
  2,786
  2,961
  3,143
  3,333
  3,531
  3,738
  3,954
  4,180
  4,416
Discount rate, %
 
  8.00
  8.40
  8.82
  9.26
  9.72
  10.21
  10.72
  11.26
  11.82
  12.41
  13.03
  13.68
  14.37
  15.09
  15.84
  16.63
  17.46
  18.34
  19.25
  20.22
  21.23
  22.29
  23.40
  24.57
  25.80
  27.09
  28.45
  29.87
  31.36
  32.93
PV of cash for distribution, $m
 
  595
  521
  506
  485
  459
  449
  440
  424
  401
  373
  327
  295
  260
  226
  192
  160
  130
  104
  81
  62
  46
  33
  23
  16
  11
  7
  4
  3
  2
  1
Current shareholders' claim on cash, %
  100
  93.3
  88.9
  86.2
  84.8
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6
  84.6

Allscripts Healthcare Solutions, Inc. provides information technology and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions. The company’s Clinical and Financial Solutions segment provides integrated clinical software applications and financial and information solutions, which primarily include EHR-related, and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training, and electronic claims administration services. Its Population Health segment offers health management and coordinated care solutions that enable hospitals, health systems, accountable care organizations, and other care facilities to connect, transition, analyze, and coordinate care across the entire care community. The company serves physicians, hospitals, governments, health systems, health plans, life-sciences companies, retail clinics, retail pharmacies, pharmacy benefit managers, insurance companies, and employer wellness clinics, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

FINANCIAL RATIOS  of  Allscripts Healthcare Solutions (MDRX)

Valuation Ratios
P/E Ratio 782.2
Price to Sales 1.5
Price to Book 1.9
Price to Tangible Book
Price to Cash Flow 8.7
Price to Free Cash Flow 17.9
Growth Rates
Sales Growth Rate 11.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 102.9%
Cap. Spend. - 3 Yr. Gr. Rate 3.5%
Financial Strength
Quick Ratio 4
Current Ratio 0
LT Debt to Equity 105.8%
Total Debt to Equity 108%
Interest Coverage 1
Management Effectiveness
Return On Assets -0.2%
Ret/ On Assets - 3 Yr. Avg. -1.2%
Return On Total Capital 0.1%
Ret/ On T. Cap. - 3 Yr. Avg. -1.2%
Return On Equity 0.2%
Return On Equity - 3 Yr. Avg. -1.7%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 43.3%
Gross Margin - 3 Yr. Avg. 41.6%
EBITDA Margin 12.8%
EBITDA Margin - 3 Yr. Avg. 11.5%
Operating Margin 3.9%
Oper. Margin - 3 Yr. Avg. 1.1%
Pre-Tax Margin -1%
Pre-Tax Margin - 3 Yr. Avg. -1.9%
Net Profit Margin 0.2%
Net Profit Margin - 3 Yr. Avg. -1.6%
Effective Tax Rate 120%
Eff/ Tax Rate - 3 Yr. Avg. 141%
Payout Ratio 0%

MDRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MDRX stock intrinsic value calculation we used $1550 million for the last fiscal year's total revenue generated by Allscripts Healthcare Solutions. The default revenue input number comes from 2016 income statement of Allscripts Healthcare Solutions. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MDRX stock valuation model: a) initial revenue growth rate of 19.4% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 8%, whose default value for MDRX is calculated based on our internal credit rating of Allscripts Healthcare Solutions, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Allscripts Healthcare Solutions.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MDRX stock the variable cost ratio is equal to 82.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $219 million in the base year in the intrinsic value calculation for MDRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 4.3% for Allscripts Healthcare Solutions.

Corporate tax rate of 27% is the nominal tax rate for Allscripts Healthcare Solutions. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MDRX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MDRX are equal to 52%.

Life of production assets of 13.8 years is the average useful life of capital assets used in Allscripts Healthcare Solutions operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MDRX is equal to -8.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1232 million for Allscripts Healthcare Solutions - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 184.853 million for Allscripts Healthcare Solutions is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Allscripts Healthcare Solutions at the current share price and the inputted number of shares is $2.4 billion.

RELATED COMPANIES Price Int.Val. Rating
CERN Cerner 63.96 43.60  sell
QSII Quality System 15.92 3.99  str.sell
CPSI Computer Progr 29.35 21.06  sell
UNH UnitedHealth G 193.77 203.69  hold
STRM Streamline Hea 1.15 0.07  str.sell
MTBC Medical Transc 1.47 0.12  str.sell
NH NantHealth 3.18 0.59  str.sell
MMM 3M 207.92 143.59  sell
MCK McKesson 147.64 1,266.10  str.buy
ATHN athenahealth 144.18 35.34  str.sell

COMPANY NEWS

▶ Allscripts to hold meeting for investors on August 8   [Aug-07-17 04:01PM  GlobeNewswire]
▶ AllScripts reports 2Q loss   [02:32AM  Associated Press]
▶ Allscripts announces second quarter 2017 results   [Aug-03-17 04:04PM  GlobeNewswire]
▶ Benzinga's Option Alert Recap From June 23   [Jun-23-17 04:09PM  Benzinga]
▶ Allscripts names new director   [May-24-17 04:01PM  GlobeNewswire]
▶ Allscripts to present at upcoming investor events   [May-17-17 08:01AM  GlobeNewswire]
▶ AllScripts reports 1Q loss   [May-04-17 05:01PM  Associated Press]
▶ AllScripts reports 4Q loss   [04:52PM  AP]
▶ [$$] Allscripts Revenue Rises on Netsmart Acquisition   [04:40PM  at The Wall Street Journal]
▶ [$$] Allscripts: Curb Your Enthusiasm   [11:04AM  at Barrons.com]
▶ Allscripts to extend EMR offerings in Australia   [Dec-04-16 04:30PM  GlobeNewswire]
▶ Hedge Funds Arent Crazy About BGC Partners, Inc. (BGCP) Anymore   [Dec-02-16 08:59AM  at Insider Monkey]
▶ Should You Buy Summit Materials Inc (SUM)?   [Dec-01-16 03:46PM  at Insider Monkey]
▶ Allscripts Announces Expanded Share Repurchase Program   [Nov-17-16 04:15PM  GlobeNewswire]
Stock chart of MDRX Financial statements of MDRX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.